Market Place
Sourcing Support
CNBX to Enter the Cancer Immunotherapy Market After Acquiring TaGeza Biopharma
08 Nov 2022 //
BIOSPACE
CNBX Files PCT Patent Application For Cannabinoids Neoadjuvant Cancer Therapy
18 Oct 2022 //
PRNEWSWIRE
CNBX Patent Application Composition for Treating Cancer
13 Oct 2022 //
PRNEWSWIRE
CNBX Pharmaceuticals Announces New Patent Granted in Australia
28 Sep 2022 //
PRNEWSWIRE
CNBX Pharmaceuticals Release a New Corporate Presentation
31 May 2022 //
PRNEWSWIRE
CNBX Pharmaceuticals Granted Patent in Hong Kong
05 May 2022 //
PRNEWSWIRE
Cannabics Pharmaceuticals Changes Name to CNBX Pharmaceuticals
28 Mar 2022 //
PRNEWSWIRE
Cannabics Pharmaceuticals Files 2 Provisional Patents for Treating Cancer
18 Oct 2021 //
PRNEWSWIRE
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
30 Sep 2021 //
PRNEWSWIRE
Gabriel Yariv and Dr. David Sans will participate at the ICDP Summit in Boston
22 Sep 2021 //
PRNEWSWIRE
Cannabics hires Dr. David Sans in New York to expand CNBX
21 Sep 2021 //
PRNEWSWIRE
Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics` Board of Advisors
23 Aug 2021 //
PRNEWSWIRE
Famous Melanoma Expert Joins Cannabics Pharmaceuticals` Board of Advisors
04 Aug 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
07 Jul 2021 //
PR NEWSWIRE
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
07 Jul 2021 //
PR NEWSWIRE
Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member
07 Jul 2021 //
PR NEWSWIRE
Cannabics Pharmaceuticals` Drug Candidate Exhibits 30% Tumor Volume Reduction
28 Jun 2021 //
PR NEWSWIRE
Neurophth announced the first patient has been dosed in G.O.L.D. clinical trial
28 Jun 2021 //
PR NEWSWIRE
Cannabics to launch Drug Development Programs for Prostate Cancer
17 Jun 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program
03 Jun 2021 //
PRNEWSWIRE
The European Patent Office Grants Cannabics Pharmaceuticals Patent
25 May 2021 //
PRNEWSWIRE
Cannabics Files a PCT Patent Application for Proprietary Cancer Formulations
11 May 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From (IMPI)
06 May 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma
26 Apr 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program
20 Apr 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals` Drug Candidate RCC-33 Prolongs Survival Rate
17 Mar 2021 //
PRNEWSWIRE
Cannabics ` Drug Candidate RCC-33 Prolongs Survival Rate in Mice
17 Mar 2021 //
PRNEWSWIRE
Cannabics Pharmaceuticals` in-vivo Study concludes with a 33% Lower Tumor
17 Feb 2021 //
PRNEWSWIRE
Cannabics ` in-vivo Study concludes with a 33% Lower Tumor Volume
16 Feb 2021 //
PRNEWSWIRE
Cannabics Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice
03 Feb 2021 //
PRNEWSWIRE
Cannabics Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
22 Dec 2020 //
PRNEWSWIRE
Cannabics Concludes a Pre-Clinical Study on Human Biopsies in for FDA pre-IND
09 Nov 2020 //
PRNEWSWIRE
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting
21 Oct 2020 //
PRNEWSWIRE
Cannabics Prepares to Submit the FDA with a pre-IND Request CANNABICS™ RCC-33
21 Oct 2020 //
PRNEWSWIRE
Cannabics to Establish a Division for its Antitumor Drug Candidate RCC-33
20 Aug 2020 //
PRNEWSWIRE
Cannabics to Capitalize on Israel`s Final Approval for the Export
26 May 2020 //
PR NEWSWIRE
Cannabics Pharmaceuticals to Capitalize on Israel`s Final Approval
26 May 2020 //
PR NEWSWIRE
Cannabics Pharma Develops Novel Cannabis Formulation for Colon Cancer
13 Apr 2020 //
PRNEWSWIRE
